BioNxt Solutions Unveils Accelerated 90-Day Plan: Global Patent Advancements, MS Clinical Trial, and Anti-Aging Expansion

VANCOUVER, BC / ACCESS Newswire / February 19, 2025 / BioNxt Solutions Inc. ('BioNxt' or the 'Company') (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to report on several major milestones for the next 90 days, including the registration of national-level patents, the completion of a human bioequivalence study for its lead Multiple Sclerosis (MS) treatment, and the development of its longevity and anti-aging product.
Global Patent Filings: Accelerating Commercial Pathways for BioNxt's Pipeline
BioNxt confirm that all national-level filings pursuant to the Patent Cooperation Treaty (PCT) are complete in key jurisdictions of interest, including the United States, Canada, Australia, Europe, and Japan. The Company's national-level filings are based on the positive international examination report issued by the European Patent Office (EPO) in Q3 2024 for the Company's comprehensive patent application for sublingual delivery of anticancer drugs for the treatment of autoimmune neurodegenerative diseases, such as MS. The Company is working to accelerate the processing and registration of national-level patents with updates to be provided as they develop.
Securing nation-level patents in premier pharmaceutical markets around the globe is a central milestone for BioNxt and will serve as the foundation for commercial opportunities for the Company's pipeline of sublingual products targeting autoimmune diseases such as multiple sclerosis (MS), myasthenia gravis (MG), lupus nephritis (LN) and rheumatoid arthritis (RA).
Human Bioequivalence Study for Lead Multiple Sclerosis Product
BioNxt's lead product, BNT23001, is a proprietary sublingual thin-film formulation of Cladribine for the treatment of MS. Preclinical studies, as reported in internal research data and third-party evaluations, have demonstrated high absorption rates and bioequivalence to existing oral therapies, with plans underway to commence the first clinical trial in the next 90 days. The bioequivalence study is relatively short and scheduled for less than 30 days from start to finish.
Successful completion of the Company's sublingual Cladribine bioequivalence study is a major milestone for the Company and a proof-of-concept demonstration for BioNxt's lead product and its pipeline of sublingual products targeting autoimmune diseases.
Expansion into Longevity and Anti-Aging
In the next 90 days, BioNxt plans to enter the rapidly growing longevity and anti-aging sector, projected to reach $93-billion (U.S.) by 2027 (Statista). The company is advancing proprietary sublingual (thin-film) and oral (enteric-coated tablet) drug products with active pharmaceutical ingredients that show early-stage evidence of benefits such as slowing ovarian aging, extending fertility and promoting healthy aging. These innovative solutions are tailored to meet the growing demand for effective anti-aging therapies.
The Company's longevity and anti-aging programs represent a strategic and diversified investment in a large and rapidly growing global market. BioNxt looks forward to providing further details in the coming weeks.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange:BNXT, OTC Markets:BNXTF and trades in Germany under WKN:A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Phone: +1 778.598.2698
Cautionary Statement Regarding 'Forward-Looking' Information
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the development, testing, regulatory approval, and commercialization of BioNxt's sublingual drug products, as well as projected milestones, anticipated partnerships, and potential market opportunities. Forward-looking statements are inherently subject to significant risks, uncertainties, and assumptions, many of which are beyond BioNxt's control. Factors that could cause actual results to differ materially include, but are not limited to, delays in regulatory approvals, negative outcomes from clinical trials, changes in market demand, fluctuations in funding availability, or disruptions in supply chains. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results may differ materially from those expressed or implied. BioNxt undertakes no obligation to update or revise forward-looking statements, except as required by law. Factors that could cause actual results to differ materially from those projected include changes in market demand, regulatory developments, delays in clinical trials, fluctuations in financing availability, supply chain disruptions, and unforeseen competitive pressures.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Associated Press

11 hours ago

• Associated Press

Does Hospital Indemnity Insurance Help Cover Recurring Stays?

NEW YORK, NY / ACCESS Newswire / June 21, 2025 / A three-day stay in the hospital costs an average of $30,000 in the United States.1 While health insurance can help reduce your out-of-pocket costs if you have to be admitted to the hospital, there are contingent costs that may not be covered by your insurer. The cost of hospital stays, and other expenses like childcare could have a significant impact while you are unable to work. A hospital indemnity insurance policy can help with these costs. Here, we explore what health insurance helps cover and how the cash benefits of hospital indemnity insurance can help fill coverage gaps relating to recurring hospital stays. What does health insurance help cover? Many people receive health insurance through their employer, which can help with the cost of a hospital stay. Employer-sponsored health insurance plans cost an average of $111 per month, while Marketplace plans cost an average of $456 per month.2 So, if you're wondering, " How much is health insurance ?,' the answer depends on your specific circumstances and plan options. Marketplace health insurance plans typically cover a range of essential health benefits, including:3 Outpatient services Emergency services Hospitalization for surgery or overnight stays Pregnancy, maternity and newborn care Mental health and behavioral health treatment Prescription drugs Rehabilitative and habilitative services and devices Laboratory services Preventive and wellness services Chronic disease management Pediatric services Hospital costs are usually covered at least in part by primary health insurance plans, but you'll still have to pay copays and deductibles, and your health insurance plan may be subject to coverage limits. What is hospital indemnity insurance? Hospital indemnity insurance is a supplemental plan that can help fill gaps in your primary health insurance. It's not a replacement for health insurance but can help you with unexpected expenses and provide additional support if you've had multiple hospital stays that forced you to reach a coverage limit. Hospital indemnity insurance works similarly to health insurance in that you pay premiums to an insurance provider in exchange for coverage. You may have access to a plan through your employer, or you can purchase an individual plan directly from an insurance company. Unlike health insurance, however, hospital indemnity insurance plans typically pay eligible cash benefits based on the policy option you choose. You can use the benefits in any way you see fit, such as: Out-of-pocket medical expenses Childcare Living expenses like groceries, rent and utilities Plans may function differently between providers, but typically, you can file a claim for care provided while in the hospital, and your insurance provider pays eligible claims to help you with the costs of your hospital stay. Why is hospital indemnity insurance worth it? There are a number of reasons why you might consider a hospital indemnity insurance plan. These may include: Added financial assistance: Hospital stays can be expensive, especially if you have to go multiple times in the same year. Hospital indemnity insurance helps provide added financial support for recurring visits. Flexibility: Health insurance plans typically pay the hospital directly for treatment. But hospital indemnity insurance pays cash benefits direct to the policyholder, unless otherwise assigned, so you can use it for both medical and non-medical costs. Surpassing coverage limits: If you've reached a health insurance coverage limit after being admitted to the hospital several times, you could still use the hospital indemnity insurance. Ultimately, if you think you or a family member will have multiple stays at the hospital in a given year, hospital indemnity insurance could help provide some added peace of mind. The bottom line Hospital indemnity insurance provides coverage options that can help with recurring hospital stays. This supplemental policy pays cash benefits direct to the policyholder, unless otherwise assigned, so you can use your benefits to help fill gaps in your health insurance coverage or help pay living expenses. Consider applying for a hospital indemnity insurance policy for added peace of mind. Sources: 1 - Why health insurance is important. Accessed May 12, 2025. 2 Ramsey Solutions - How Much Does Health Insurance Cost? Updated May 12, 2025. Accessed May 12, 2025. 3 - Health benefits & coverage. Accessed May 12, 2025. Content within this article is provided for general informational purposes and is not provided as tax, legal, health, or financial advice for any person or for any specific situation. Employers, employees, and other individuals should contact their own advisers about their situations. For complete details, including availability and costs of Aflac insurance, please contact your local Aflac agent. Aflac coverage is underwritten by American Family Life Assurance Company of Columbus. In New York, Aflac coverage is underwritten by American Family Life Assurance Company of New York. Hospital, B40000 series: In Delaware, Policies B40100DE & B4010HDE. In Idaho, Policies B40100ID & B4010HID. In Oklahoma, Policies B40100OK & B4010HOK. In Pennsylvania, Policies B40100PA & B4010HPA. In Virginia, Policies B40100VA & B4010HVA. Coverage may not be available in all states, including but not limited to DE, ID, NJ, NM, NY, VA or VT. Benefits/premium rates may vary based on state and plan levels. Optional riders may be available at an additional cost. Policies and riders may also contain a waiting period. Refer to the exact policy and rider forms for benefit details, definitions, limitations, and exclusions. Aflac WWHQ | 1932 Wynnton Road | Columbus, GA 31999 CONTACT: Senior PR & Corporate Communications Contact: Angie Blackmar, 706-392-2097 or [email protected] SOURCE: Aflac press release

Business Insider

14 hours ago

• Business Insider

Morgan Stanley Reaffirms Their Sell Rating on MS&AD Insurance Group Holdings (MSADF)

Morgan Stanley analyst Mia Nagasaka maintained a Sell rating on MS&AD Insurance Group Holdings (MSADF – Research Report) yesterday and set a price target of Yen3,380.00. The company's shares closed yesterday at $22.47. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Nagasaka is a 2-star analyst with an average return of -0.5% and a 57.14% success rate. Nagasaka covers the Financial sector, focusing on stocks such as MS&AD Insurance Group Holdings, Chiba Bank, and Dai-ichi Life Holdings. MS&AD Insurance Group Holdings has an analyst consensus of Moderate Sell, with a price target consensus of $25.09.

Associated Press

a day ago

• Associated Press

Rush Gold Completes Initial Public Offering and Listing on CSE

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / June 20, 2025 / Rush Gold Corp. (the 'Corporation' or 'Rush') (CSE:RGN) is pleased to announce that it has completed its initial public offering (the 'Offering') of 4,500,000 common shares of the Corporation (each a 'Common Share') at a purchase price of $0.10 per Common Share, for gross proceeds (the 'Gross Proceeds') of $450,000. The Common Shares were listed on the Canadian Securities Exchange (the 'CSE') at the market open on June 20, 2025 and immediately halt traded pending closing of the Offering. The halt is expected to be lifted and trading of the Common Shares on the CSE is expected to commence on June 23, 2025 under the symbol 'RGN'. The Company intends to use the net proceeds from the Offering towards exploration of the Corporation's Skylight gold property, for general and administrative purposes and for working capital purposes, all as set out in more detail in the Corporation's final long form prospectus dated May 16, 2025 (the 'Prospectus'), filed in each of the provinces of British Columbia, Alberta and Ontario. Research Capital Corporation (the 'Agent') acted as agent for the Offering, pursuant to an agency agreement between the Agent and the Corporation dated May 16, 2025. In consideration for the services provided by the Agent, the Corporation: (i) paid the Agent a $45,000 cash commission, which is equal to 10% of the Gross Proceeds; (ii) paid the Agent a corporate finance fee of $29,925, inclusive of applicable taxes; (iii) issued the Agent 250,000 Common Shares with an aggregate deemed value of $25,000; and (iv) granted the Agent an option to acquire up to 450,000 Common Shares at a price of $0.10 per Common Share until June 20, 2027. As of the date hereof, the Corporation has 15,493,500 Common Shares issued and outstanding, of which 4,605,000 are escrowed pursuant to an escrow agreement among the Corporation, certain principals of the Corporation and Endeavor Trust Corporation dated May 16, 2025. Anthony Zelen, CEO of Rush, commented: 'Today marks a pivotal moment for Rush Gold, as we have completed our IPO and are set to commence trading on the CSE under the ticker symbol 'RGN' on June 23, 2025. As gold prices have recently reached all-time highs, we believe our listing is well-timed. We are eager to begin exploration at our Skylight gold property in Nevada.' For further information, please see the Prospectus, available under the Corporation's profile on SEDAR+ at The offered securities were not and will not be registered under the United States Securities Act of 1933, as amended (the 'U.S. Securities Act'), or any applicable state securities laws and may not be offered or sold in the United States or to 'U.S. persons', as such term is defined in Regulation S under the U.S. Securities Act, absent such registration or an applicable exemption from such registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy the offered securities in any jurisdiction. About Rush Gold Corp. Rush Gold Corp. is a Canadian mining exploration company focused on advancing its Skylight gold property, located in the Republic Mining District, Nye County, Nevada, in the United States of America. For further information, please contact: Anthony Zelen Director and Chief Executive Officer T: (778) 388 5258 E: [email protected] Forward-Looking Statements The information in this news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute forward-looking statements, including statements respecting the anticipated trade date for the Common Shares on the CSE, the expected use of proceeds from the Offering and the Company's plans for its Skylight property. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward-looking statements. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Corporation believes that the expectations reflected in forward-looking statements are reasonable, it can give no assurances that the expectations of any forward-looking statements will prove to be correct. Except as required by law, the Corporation disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise. The Canadian Securities Exchange has not reviewed this press release and does not accept responsibility for the adequacy or accuracy of this news release. SOURCE: Rush Gold Corp. press release